Does Insurance Cover Yervoy?
Yervoy (ipilimumab), a Bristol Myers Squibb immunotherapy for melanoma and other cancers, is typically covered by most U.S. private insurance plans, Medicare Part B, and Medicaid, but coverage depends on medical necessity, prior authorization, and specific plan details.[1][2]
Which Insurances Usually Cover Yervoy?
- Medicare: Covered under Part B for FDA-approved uses like advanced melanoma, with patients paying 20% coinsurance after deductible (around $240 in 2024). Supplemental Medigap plans can reduce this.[1][3]
- Medicaid: Varies by state; most cover it for eligible patients, often with low or no copays.[2]
- Private Insurance (e.g., Blue Cross, UnitedHealthcare): Commonly covered if criteria like confirmed diagnosis and failed prior treatments are met. Prior authorization is standard.[1][4]
- VA and Tricare: Fully covered for eligible veterans and military members.[3]
Check your plan's formulary via the insurer's portal or app.
What If Your Insurance Denies Coverage?
Denials happen for off-label use, lack of prior authorization, or step therapy requirements (trying cheaper drugs first). Appeal with your doctor's letter of medical necessity, including clinical trial data or guidelines from NCCN.[1][5] Success rate for cancer drug appeals exceeds 50%.[4]
How Much Does Yervoy Cost Without Insurance?
A single infusion cycle (4 mg/kg every 3 weeks for 4 doses) lists at $158,000-$165,000, per Drugs.com and GoodRx data. Patient assistance programs like Bristol Myers' Access Support cover copays or provide free drug for uninsured/underinsured.[6][7]
Yervoy Copays and Financial Assistance Options
| Insurance Type | Typical Copay/Out-of-Pocket |
|---------------|-----------------------------|
| Commercial (Tier 3/4 specialty) | $100-$5,000 per month (capped at $10,650/year under ACA for 2024) [4] |
| Medicare Part B | 20% of $30,000-$40,000 per dose (~$6,000-$8,000/dose) [1] |
| With copay cards | $0-$5 per infusion [7] |
Bristol Myers' OneOncology or PAN Foundation grants help; apply via yervoy.com/support.[6]
Factors Affecting Coverage Approval
Oncology guidelines (NCCN Category 1 for melanoma) boost approval odds. Biosimilars aren't available yet—patent expires around 2028, per DrugPatentWatch.[8] Off-label use (e.g., some kidney cancers) faces higher scrutiny.[5]
Sources
[1]: CMS Medicare Coverage for Ipilimumab
[2]: Medicaid.gov Drug Coverage
[3]: CancerCare.org Yervoy Guide
[4]: GoodRx Yervoy Pricing
[5]: NCCN Guidelines for Melanoma
[6]: Bristol Myers Squibb Access Support
[7]: Drugs.com Yervoy Prices
[8]: DrugPatentWatch.com - Yervoy Patents